Antiretroviral therapy: Effects on orofacial health and health care

Oral Diseases

Volumn 20, Issue 2, 2014, Pages 136-145

  Diz Dios, P ^a   Scully, C ^b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adverse effects; AIDS; Antiretroviral; HIV; Oral cavity

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CHEMICALLY INDUCED; HEALTH CARE DELIVERY; HUMAN; MOUTH DISEASE; SKIN DISEASE;

ANTI-HIV AGENTS; DELIVERY OF HEALTH CARE; FACIAL DERMATOSES; HUMANS; MOUTH DISEASES;

EID: 84893764257     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12093     Document Type: Review

References (56)

1. Aptivus (2008). [package insert]. Boehringer Ingelheim Pharmaceuticals: Ingelheim, Germany.
2. Ayangco LL, Rogers RS (2003). Oral manifestations of erythema multiforme. Dermatol Clin 21: 195-205.
3. Berkhout B, Eggink D, Sanders RW (2012). Is there a future for antiviral fusion inhibitors? Curr Opin Virol 2: 50-59.
4. Borras-Blasco J, Belda A, Rosique-Robles JD, Castera E, Abad FJ (2006). Burning mouth syndrome due to efavirenz therapy. Ann Pharmacother 40: 1471-1472.
5. Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JAM, Koopmans PP (1998). Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12: 1735-1744.
6. Cameron DW, Japour AJ, Xu Y et al (1999). Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13: 213-224.
7. Carr A, Cooper DA (2000). Adverse effects of antiretroviral therapy. Lancet 356: 1423-1430.
8. Cartsos VM, Palaska PK, Zavras AI (2012). Antiretroviral prophylaxis and the risk of cleft lip and palate: preliminary signal detection in the Food and Drug Administration's adverse events reporting system database. Cleft Palate Craniofac J 49: 118-121.
9. Celsentri (2012). [package insert]. ViiV Healthcare UK: Brentford, Middlesex, UK.
10. Chene G, Angelini E, Cotte L et al (2002). Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 34: 649-657.
11. Cocohoba J, Dong BJ (2008). Raltegravir: the first HIV integrase inhibitor. Clin Ther 30: 1747-1765.
12. Cunningham AL, Taghi AS, Singh GK, Sandison A, Cohen CE, Grant WE (2012). Surgical management of bilateral parotid lipomatosis in a patient with HIV. Head Neck. [Epub ahead of print].
13. Danner SA, Carr A, Leonard JM et al (1995). A short-term study of the safety, pharmacokinetics and efficacy of ritonavir, an ihibitor of HIV-1 protease. N Engl J Med 333: 1528-1533.
14. Diz Dios P, Scully C (2002). Adverse effects of antiretroviral therapy: focus on orofacial effects. Expert Opin Drug Saf 1: 307-317.
15. Dodd CL, Greenspan D, Westenhause JL, Katz MH (1992). Xerostomia associated with didanosine. Lancet 340: 790.
16. Edurant (2011). [package insert]. Tibotec Therapeutics: Titusville, NJ.
17. Epstein JB, Scully C (1993). Oral adverse effects of medical management in patients with HIV infection. AIDS Patient Care 7: 304-311.
18. Espona M, Ferrández O, Grau S, Carmona A (2005). Enfuvirtida: primer fármaco de una nueva familia de antirretrovirales. Farm Hosp 29: 375-383.
19. Ficarra G, Flaitz CM, Gaglioti D et al (1993). White lichenoid lesions of the buccal mucosa in patients with HIV infection. Oral Surg, Oral Med, Oral Pathol 76: 460-466.
20. Flint OP, Noor MA, Hruz PW et al (2009). The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol 37: 65-77.
21. Fox PA, Hawkins DA, Staughton RC (2000). Cheilitis in association with indinavir. Sex Transm Infect 76: 323-324.
22. Friday D, Evans-Jones J, Steedman N (2012). Are we constructing the best treatment regimens for all patients with HIV infection? J Int AIDS Soc 15(Suppl 4): 18095.
23. Fung HB, Guo Y (2004). Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther 26: 352-378.
24. González-Martín G, Yañez CG, González-Contreras L, Labarca J (1999). Adverse drug reactions (ADRs) in patients with HIV infection. A prospective study. Int J Clin Pharmacol Ther 37: 34-40.
25. Goodgame JC, Pottage JC Jr, Jablonowski H et al (2000). Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team. Antivir Ther 5: 215-225.
26. Grant M, Samuel R, Bettiker RL, Suh B (2011). Antiretroviral therapy 2010 update: current practices and controversies. Arch Pharm Res 34: 1045-1053.
27. Greenberg RG, Berger TG (1990). Nail and mucocutaneous hyperpigmentation with azidothymidine therapy. J Am Acad Dermatol 22: 327-330.
28. Hetherington S, Hughes AR, Mosteller M et al (2002). Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359: 1121-1122.
29. Intelence (2008). [package insert]. Tibotec Therapeutics: Titusville, NJ.
30. Introcaso CE, Hines JM, Kovarik CL (2010a). Cutaneous toxicities of antiretroviral therapy for HIV. Part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors. J Am Acad Dermatol 63: 549-561.
31. Introcaso CE, Hines JM, Kovarik CL (2010b). Cutaneous toxicities of antiretroviral therapy for HIV: Part II. Nonnucleoside reverse transcriptase inhibitors, entry and fusion inhibitors, integrase inhibitors, and immune reconstitution syndrome. J Am Acad Dermatol 63: 563-569.
32. Isentress (2011). [package insert]. Merck Sharp & Dohme Corp: Whitehouse Station, NJ, USA.
33. Kong HH, Myers SA (2005). Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients. Dermatol Ther 18: 58-66.
34. Makinson A, Reynes J (2009). The fusion inhibitor enfuvirtide in recent antiretroviral strategies. Curr Opin HIV AIDS 4: 150-158.
35. Manzardo C, Zaccarelli M, Agüero F, Antinori A, Miró JM (2007). Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease. J Acquir Immune Defic Syndr 46(Suppl 1): S9-18.
36. Max B, Sherer R (2000). Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 30(Suppl 2): S96-116.
37. Moura MD, Senna MI, Madureira DF, Fonseca LM, Mesquita RA (2008). Oral adverse effects due to the use of nevirapine. J Contemp Dent Pract 9: 84-89.
38. Murri R, Ammassari A, Gallicano K et al (2000). Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr 24: 123-128.
39. Navazesh M, Mulligan R, Karim R et al (2009). Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS). Oral Dis 15: 52-60.
40. Nittayananta W, Talungchit S, Jaruratanasirikul S et al (2010). Effects of long-term use of HAART on oral health status of HIV-infected subjects. J Oral Pathol Med 39: 397-406.
41. Olive A, Salavert A, Manriquez M, Clotet B, Moragas A (1998). Parotid lipomatosis in HIV positive patients: a new clinical disorder associated with protease inhibitors. Ann Rheum Dis 57: 749.
42. Parra J, Portilla J, Pulido F et al (2011). Clinical utility of maraviroc. Clin Drug Investig 31: 527-542.
43. Pavlos R, Phillips EJ (2011). Individualization of antiretroviral therapy. Pharmgenomics Pers Med 5: 1-17.
44. Porter SR, Scully C (1998). HIV topic update: protease inhibitor therapy and oral health care. Oral Dis 4: 159-163.
45. Prezista (2006). [package insert]. Tibotec Therapeutics: Titusville, NJ, USA.
46. Rashbaum B (2005). Evaluation of hyperpigmentation in HIV-infected patients receiving emtricitabine. Presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24-27: Río de Janeiro, Brasil. Abstract No. TuPe2.4C15.
47. Reynes J, Arastéh K, Clotet B et al (2007). TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 21: 533-543.
48. Schiffman SS, Zervakis J, Heffron S, Heald AE (1999). Effect of protease inhibitors on the sense of taste. Nutrition 15: 767-772.
49. Schwander S, Kern P (1993). Tongue ulcer in azidothymidine induced neutropenia. Rapid increase in neutrophils and healing of the ulcer by substitution of recombinant human granulocyte colony stimulating factor (rhG-CSF)]. Med Klin 88: 60-62.
50. Scully C, Diz Dios P (2001). HIV topic update: orofacial effects of antiretroviral therapies. Oral Dis 7: 205-210.
51. Sturm LP, Cooter RD, Mutimer KL, Graham JC, Maddern GJ (2009). A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy. AIDS Patient Care STDS 23: 699-714.
52. Teppler H, Brown DD, Leavitt RY et al (2011). Long-term safety from the raltegravir clinical development program. Curr HIV Res 9: 40-53.
53. Thompson MA, Aberg JA, Hoy JF et al (2012). Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308: 387-402.
54. UNAIDS (2011). Global HIV/AIDS response: epidemic update and health sector progress towards Universal Access. Progress Report 2011. UNAIDS, Geneva. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20111130_UA_Report_en.pdf [accessed on 9 January 2013].
55. UNAIDS (2012). Global report: UNAIDS report on the global AIDS epidemic 2012. UNAIDS, Geneva. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf. [accessed on 7 January 2013].
56. Wasmuth JC, Rockstroh JK, Hardy WD (2012). Drug safety evaluation of maraviroc for the treatment of HIV infection. Expert Opin Drug Saf 11: 161-174.